Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 186

As part of its ongoing work to track variants, WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) met on the 24 October 2022 to discuss the latest evidence on the Omicron variant of concern, and how its evolution is currently unfolding, in light of high levels of population immunity in many settings and country differences in the immune landscape. In particular, the public health implications of the rise of some Omicron variants, specifically XBB and its sublineages (indicated as XBB•, as well as BQ.1 and its sublineages (indicated as BQ.1•, were discussed. Based on currently available evidence, the TAG-VE does not feel that the overall phenotype of XBB* and BQ.1* diverge sufficiently from each other, or from other Omicron lineages with additional immune escape mutations, in terms of the necessary public health response, to warrant the designation of new variants of concern and assignment of a new label. The two sublineages remain part of Omicron, which continues to be a variant of concern. This decision will be reassessed regularly. If there is any significant development that warrant a change in public health strategy, WHO will promptly alert Member States and the public. XBB*XBB* is a recombinant of BA.2.10.1 and BA.2.75 sublineages. As of epidemiological week 40 (3 to 9 October), from the sequences submitted to GISAID, XBB* has a global prevalence of 1.3% and it has been detected in 35 countries. The TAG-VE discussed the available data on the growth advantage of this sublineage, and some early evidence on clinical severity and reinfection risk from Singapore and India, as well as inputs from other countries. There has been a broad increase in prevalence of XBB* in regional genomic surveillance, but it has not yet been consistently associated with an increase in new infections. While further studies are needed, the current data do not suggest there are substantial differences in disease severity for XBB* infections. There is, however, early evidence pointing at a higher reinfection risk, as compared to other circulating Omicron sublineages. Cases of reinfection were primarily limited to those with initial infection in the pre-Omicron period. As of now, there are no data to support escape from recent immune responses induced by other Omicron lineages. Whether the increased immune escape of XBB* is sufficient to drive new infection waves appears to depend on the regional immune landscape as affected by the size and timing of previous Omicron waves, as well as the COVID-19 vaccination coverage. BQ.1*BQ.1* is a sublineage of BA.5, which carries spike mutations in some key antigenic sites, including K444T and N460K. In addition to these mutations, the sublineage BQ.1.1 carries an additional spike mutation in a key antigenic site (i.e. R346T). As of epidemiological week 40 (3 to 9 October), from the sequences submitted to GISAID, BQ.1* has a prevalence of 6% and it has been detected in 65 countries. While there are no data on severity or immune escape from studies in humans, BQ.1* is showing a significant growth advantage over other circulating Omicron sublineages in many settings, including Europe and the US, and therefore warrants close monitoring. It is likely that these additional mutations have conferred an immune escape advantage over other circulating Omicron sublineages, and therefore a higher reinfection risk is a possibility that needs further investigation. At this time there is no epidemiologic data to suggest an increase in disease severity. The impact of the observed immunological changes on vaccine escape remains to be established. Based on currently available knowledge, protection by vaccines (both the index and the recently introduced bivalent vaccines) against infection may be reduced but no major impact on protection against severe disease is foreseen. Overall summaryThe Omicron variant of concern remains the dominant variant circulating globally, accounting for nearly all sequences reported to GISAID[1]. While we are looking at a vast genetic diversity of Omicron sublineages, they currently display similar clinical outcomes, but with differences in immune escape potential. The potential impact of these variants is strongly influenced by the regional immune landscape. While reinfections have become an increasingly higher proportion of all infections, this is primarily seen in the background of non-Omicron primary infections. With waning immune response from initial waves of Omicron infection, and further evolution of Omicron variants, it is likely that reinfections may rise further. The role of the TAG-VE is to alert WHO if a variant with a substantially different phenotype (e.g. a variant that can cause a more severe disease or lead to large epidemic waves causing increased burden to the healthcare system) is emerging and likely to pose a significant threat. Based on currently available evidence, the TAG-VE does not feel that the overall phenotype of XBB* and BQ.1* diverge sufficiently from each other, or from other Omicron sublineages with additional immune escape mutations, in terms of the necessary public health response, to warrant the designation of a new variant of concern and assignment of a new label, but the situation will be reassessed regularly. We note these two sublineages remain part of Omicron, which is a variant of concern with very high reinfection and vaccination breakthrough potential, and surges in new infections should be handled accordingly. While so far there is no epidemiological evidence that these sublineages will be of substantially greater risk compared to other Omicron sublineages, we note that this assessment is based on data from sentinel nations and may not be fully generalizable to other settings. Wide-ranging, systematic laboratory-based efforts are urgently needed to make such determinations rapidly and with global interpretability. WHO will continue to closely monitor the XBB* and BQ.1* lineages as part of Omicron and requests countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative analyses of the different Omicron sublineages. The TAG-VE meets regularly and continues to assess the available data on the transmissibility, clinical severity, and immune escape potential of variants, including the potential impact on diagnostics, therapeutics, and the effectiveness of vaccines in preventing infection and/or severe disease. [1] Weekly epidemiological update on COVID-19 — 26 October 2022 (who.int)

Read more | >

Guarding Against Future Global Biological Risks — Dr. Margaret “Peggy” Hamburg, MD — Chair Nuclear Threat Initiative, bio Advisory Group; Commissioner, Bipartisan Commission on Biodefense; former Commissioner, U.S. Food and Drug Administration (FDA)

Dr. Margaret “Peggy” Hamburg, MD is an internationally recognized leader in public health and medicine, who currently serves as chair of the Nuclear Threat Initiative’s (NTI) bio Advisory Group (https://www.nti.org/about/people/margaret-hamburg-md/), where she has also served as founding vice president and senior scientist. She also currently holds a role as Commissioner on the Bipartisan Commission on Biodefense (https://biodefensecommission.org/teams/margaret-a-hamburg/).

Dr. Hamburg previously served as foreign secretary of the National Academy of Medicine and is a former Commissioner of the U.S. Food and Drug Administration (FDA), having served for almost six years where she was well known for advancing regulatory science, modernizing regulatory pathways, and globalizing the agency. Previous government positions include Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Health Commissioner for New York City, and Assistant Director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

In her role, as Foreign Secretary of the National Academy of Medicine, the health arm of the National Academy of Sciences, Engineering and Medicine, Dr. Hamburg served as senior advisor on international matters and was the liaison with other Academies of Medicine around the world. She is an elected member of the Council on Foreign Relations and the National Academy of Medicine.

Dr. Hamburg currently sits on the boards of the Commonwealth Fund, the Simons Foundation, the Urban Institute, the Global Alliance for Vaccines and Immunization, the Parker Institute for Cancer Immunotherapy and the American Museum of Natural History. She is chair of the Joint Coordinating Group for the Coalition for Epidemic Preparedness and Innovation, and a member of the Harvard University Global Advisory Council, the Global Health Scientific Advisory Committee for the Gates Foundation, the Harvard Medical School Board of Fellows, and the World Dementia Council.

Continue reading “Dr. Peggy Hamburg, MD — Chair, Nuclear Threat Initiative (NTI), bio Advisory Group” | >

This included ‘evaluating life’, such as seeing memories and assessing how they had treated others during their time alive.

Others felt like they were ‘heading to a destination’ or were even aware that CPR was being performed.

Dr Sam Parnia, study author and a critical care expert from New York medical centre NYU Langone Health, said patients can also be aware of activities in intensive care after CPR and hear medics treating them.

Read more | >

A result of the gradual increase in human lifespan and high and persistent levels of fertility in some countries.

The world’s population hit eight billion today, November 15, and this is a “milestone in human development,” according to a statement by the United Nations (UN).

This unprecedented growth is due to the gradual increase in human lifespan owing to improvements in public health, nutrition, personal hygiene, and medicine.

Dmytro Varavin/iStock.

Considering the fact that the last time the global population notched seven billion was in 2011, the world population increased by one billion in the last 11 years. This raises concerns about overpopulation, which is directly linked to climate change.

Read more | >

A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.

The Weill Cornell Medicine CAP-IT Center for LNP RNA Immunoprevention was selected as one of two founding members of the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT), a collaborative research network funded by the NCI to discover agents that prevent or intercept cancer in high-risk populations.

Read more | >

There might be room for everyone, or not. At first glance, the connections between the world’s growing population and climate change seem obvious. The more people we have on this planet, the larger their collective impact on the climate.

The global population is projected to reach 8 billion on 15 November 2022, and India is projected to surpass China as the world’s most populous country in 2023, according to World Population Prospects 2022, released today on World Population Day.

“This year’s World Population Day falls during a milestone year, when we anticipate the birth of the Earth’s eight billionth inhabitant. This is an occasion to celebrate our diversity, recognize our common humanity, and marvel at advancements in health that have extended lifespans and dramatically reduced maternal and child mortality rates,” said UN Secretary-General António Guterres. “At the same time, it is a reminder of our shared responsibility to care for our planet and a moment to reflect on where we still fall short of our commitments to one another,” he added.

The global population is growing at its slowest rate since 1950, having fallen under 1 per cent in 2020. The latest projections by the United Nations suggest that the world’s population could grow to around 8.5 billion in 2030 and 9.7 billion in 2050. It is projected to reach a peak of around 10.4 billion people during the 2080s and to remain at that level until 2100.

Read more | >

Glaucoma impacts tens of millions of people globally, and is the second leading cause of blindness, after cataracts. Now, Purdue University researchers have developed smart contact lenses that may help save people’s sight.

Glaucoma is a multifactorial optic degenerative neuropathy characterized by the loss of retinal ganglion cells. It is a combination of vascular, genetic, anatomical, and immune factors. Glaucoma poses a significant public health concern as it is the second leading cause of blindness after cataracts, and this blindness is usually irreversible. It is estimated that 57.5 million people worldwide are affected by primary open-angle glaucoma (POAG). People over 60 years of age, family members of those already diagnosed with glaucoma, steroid users, diabetics, as well as those with high myopia, hypertension, central cornea thickness of.

Read more | >

As LHC Run 3 gets into its stride and the first results at a new energy frontier roll in (p5), all eyes are on what’s next: the High-Luminosity LHC (HL-LHC), scheduled to start operations in 2029. Civil engineering for the major upgrade is complete (p7) and new crystal collimators for HL-LHC operations are to be put to the test during the current run (p35). Looking beyond the LHC, how best to deal with the millions of cubic metres of excavation materials from a future circular collider? (p9), and a new project to explore the use of high-temperature superconductors for FCC-ee (p8). The HL-LHC and proposed future colliders also feature large in the recent US Snowmass community planning exercise (p23).

Read more | >

Cheers!

𝐁𝐞𝐞𝐫 𝐈𝐧𝐠𝐫𝐞𝐝𝐢𝐞𝐧𝐭 𝐌𝐚𝐲 𝐈𝐧𝐡𝐢𝐛𝐢𝐭 𝐂𝐥𝐮𝐦𝐩𝐢𝐧𝐠 𝐨𝐟 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐏𝐫𝐨𝐭𝐞𝐢𝐧

𝘽𝙚𝙚𝙧 𝙞𝙨 𝙤𝙣𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙤𝙡𝙙𝙚𝙨𝙩 𝙖𝙣𝙙 𝙢𝙤𝙨𝙩 𝙥𝙤𝙥𝙪𝙡𝙖𝙧 𝙗𝙚𝙫𝙚𝙧𝙖𝙜𝙚𝙨 𝙞𝙣 𝙩𝙝𝙚 𝙬𝙤𝙧𝙡𝙙, 𝙬𝙞𝙩𝙝 𝙨𝙤𝙢𝙚 𝙥𝙚𝙤𝙥𝙡𝙚 𝙡𝙤𝙫𝙞𝙣𝙜 𝙖𝙣𝙙 𝙤𝙩𝙝𝙚𝙧𝙨 𝙝𝙖𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝙙𝙞𝙨𝙩𝙞𝙣𝙘𝙩, 𝙗𝙞𝙩𝙩𝙚𝙧 𝙩𝙖𝙨𝙩𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙝𝙤𝙥𝙨 𝙪𝙨𝙚𝙙 𝙩𝙤 𝙛𝙡𝙖𝙫𝙤𝙧 𝙞𝙩𝙨 𝙢𝙖𝙣𝙮 𝙫𝙖𝙧𝙞𝙚𝙩𝙞𝙚𝙨. 𝘽𝙪𝙩 𝙖𝙣 𝙚𝙨𝙥𝙚𝙘𝙞𝙖𝙡𝙡𝙮 “𝙝𝙤𝙥𝙥𝙮” 𝙗𝙧𝙚𝙬 𝙢𝙞𝙜𝙝𝙩 𝙝𝙖𝙫𝙚 𝙪𝙣𝙞𝙦𝙪𝙚 𝙝𝙚𝙖𝙡𝙩𝙝 𝙗𝙚𝙣𝙚𝙛𝙞𝙩𝙨. 𝙍𝙚𝙘𝙚𝙣𝙩 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙥𝙪𝙗𝙡𝙞𝙨𝙝𝙚𝙙 𝙞𝙣 𝘼𝘾𝙎 𝘾𝙝𝙚𝙢𝙞𝙘𝙖𝙡 𝙉𝙚𝙪𝙧𝙤𝙨𝙘𝙞𝙚𝙣𝙘𝙚 𝙧𝙚𝙥𝙤𝙧𝙩𝙨 𝙩𝙝𝙖𝙩 𝙘𝙝𝙚𝙢𝙞𝙘𝙖𝙡𝙨 𝙚𝙭𝙩𝙧𝙖𝙘𝙩𝙚𝙙 𝙛𝙧𝙤𝙢 𝙝𝙤𝙥 𝙛𝙡𝙤𝙬𝙚𝙧𝙨 𝙘𝙖𝙣, 𝙞𝙣 𝙡𝙖𝙗 𝙙𝙞𝙨𝙝𝙚𝙨, 𝙞𝙣𝙝𝙞𝙗𝙞𝙩 𝙩𝙝𝙚 𝙘𝙡𝙪𝙢𝙥𝙞𝙣𝙜 𝙤𝙛 𝙖𝙢𝙮𝙡𝙤𝙞𝙙 𝙗𝙚𝙩𝙖 𝙥𝙧𝙤𝙩𝙚𝙞𝙣𝙨, 𝙬𝙝𝙞𝙘𝙝 𝙞𝙨 𝙖𝙨𝙨𝙤𝙘𝙞𝙖𝙩𝙚𝙙 𝙬𝙞𝙩𝙝 𝘼𝙡𝙯𝙝𝙚𝙞𝙢𝙚𝙧’𝙨 𝙙𝙞𝙨𝙚𝙖𝙨𝙚 (𝘼𝘿).

Beer is one of the oldest and most popular beverages in the world, with some people loving and others hating the distinct, bitter taste of the hops used to flavor its many varieties. But an especially “hoppy” brew might have unique health benefits. Recent research published in ACS Chemical Neuroscience reports that chemicals extracted from hop flowers can, in lab dishes, inhibit the clumping of amyloid beta proteins, which is associated with Alzheimer’s disease (AD).

AD is a debilitating neurodegenerative disease, often marked by memory loss and personality changes in older adults. Part of the difficulty in treating the disease is the time lag between the start of underlying biochemical processes and the onset of symptoms, with several years separating them. This means that irreversible damage to the nervous system occurs before one even realizes they may have the disease. Accordingly, preventative strategies and therapeutics that can intervene before symptoms appear are of increasing interest.

One of these strategies involves “nutraceuticals,” or foods that have some type of medicinal or nutritional function. The hop flowers used to flavor beers have been explored as one of these potential nutraceuticals, with previous studies suggesting that the plant could interfere with the accumulation of amyloid beta proteins associated with AD. So, Cristina Airoldi, Alessandro Palmioli and colleagues wanted to investigate which chemical compounds in hops had this effect.

Continue reading “Beer Ingredient May Inhibit Clumping of Alzheimer’s Protein” | >